A new look at screening and diagnosing diabetes mellitus.

OBJECTIVE Diabetes is underdiagnosed. About one third of people with diabetes do not know they have it, and the average lag between onset and diagnosis is 7 yr. This report reconsiders the criteria for diagnosing diabetes and recommends screening criteria to make case finding easier for clinicians and patients. PARTICIPANTS R.M.B. invited experts in the area of diagnosis, monitoring, and management of diabetes to form a panel to review the literature and develop consensus regarding the screening and diagnosis of diabetes with particular reference to the use of hemoglobin A1c (HbA1c). Participants met in open session and by E-mail thereafter. Metrika, Inc. sponsored the meeting. EVIDENCE A literature search was performed using standard search engines. CONSENSUS PROCESS The panel heard each member's discussion of the issues, reviewing evidence prior to drafting conclusions. Principal conclusions were agreed on, and then specific cut points were discussed in an iterative consensus process. CONCLUSIONS The main factors in support of using HbA1c as a screening and diagnostic test include: 1) HbA1c does not require patients to be fasting; 2) HbA1c reflects longer-term glycemia than does plasma glucose; 3) HbA1c laboratory methods are now well standardized and reliable; and 4) errors caused by nonglycemic factors affecting HbA1c such as hemoglobinopathies are infrequent and can be minimized by confirming the diagnosis of diabetes with a plasma glucose (PG)-specific test. Specific recommendations include: 1) screening standards should be established that prompt further testing and closer follow-up, including fasting PG of 100 mg/dl or greater, random PG of 130 mg/dl or greater, or HbA1c greater than 6.0%; 2) HbA1c of 6.5-6.9% or greater, confirmed by a PG-specific test (fasting plasma glucose or oral glucose tolerance test), should establish the diagnosis of diabetes; and 3) HbA1c of 7% or greater, confirmed by another HbA1c- or a PG-specific test (fasting plasma glucose or oral glucose tolerance test) should establish the diagnosis of diabetes. The recommendations are offered for consideration of the clinical community and interested associations and societies.

[1]  R. Cohen.  A1C: Does One Size Fit All? R.M.C. holds stock in Novartis and Medtronic. , 2007, Diabetes Care.

[2]  W. Herman,et al.  A multivariate logistic regression equation to screen for diabetes: development and validation. , 2002, Diabetes care.

[3]  H. Halkin,et al.  Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. , 1984, American journal of epidemiology.

[4]  S. Fowler,et al.  The prevalence of retinopathy in impaired glucose tolerance and recent‐onset diabetes in the Diabetes Prevention Program , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[5]  L. Kennedy,et al.  Utility of A1C for Diabetes Screening in the 1999-2004 NHANES Population , 2008 .

[6]  N. Fineberg,et al.  HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). , 2001, Diabetes care.

[7]  D. Schriger,et al.  An Alternative Approach to the Diagnosis of Diabetes With a Review of the Literature , 1995, Diabetes Care.

[8]  D. Schriger,et al.  Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. , 1999, JAMA.

[9]  D. Owens,et al.  Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. , 1999, Diabetes care.

[10]  R. Little,et al.  Biological variation of glycohemoglobin. , 2002, Clinical chemistry.

[11]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[12]  S. Dharmage,et al.  HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[13]  C. Cook,et al.  Effects of Sickle Cell Trait and Hemoglobin C Trait on Determinations of HbA1c by an Immunoassay Method , 1998, Diabetes Care.

[14]  Darrell M. Wilson,et al.  Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study , 2005, Pediatric diabetes.

[15]  C. Jackson,et al.  The Glycohaemoglobin Assay as a Screening Test for Diabetes Mellitus: The Islington Diabetes Survey , 1987, Diabetic medicine : a journal of the British Diabetic Association.

[16]  W. Herman,et al.  The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74 years of age. , 2005, Diabetes care.

[17]  R. Hanson,et al.  Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes , 1994, BMJ.

[18]  T. Wong,et al.  Retinal Vascular Changes in Pre-Diabetes and Prehypertension , 2007, Diabetes Care.

[19]  B. Zinman,et al.  A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[20]  S. Dharmage,et al.  HbA1c as a screening tool for detection of Type 2 diabetes: a systematic review , 2007 .

[21]  Matthew D. Davis,et al.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.

[22]  John M. Lachin,et al.  Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program , 2007 .

[23]  V. Hasselblad,et al.  A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. , 1996, JAMA.

[24]  Vic Hasselblad,et al.  A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. , 1996, JAMA.

[25]  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. , 1979, Diabetes.

[26]  Ray Burke,et al.  Opportunistic screening for diabetes in routine clinical practice. , 2004, Diabetes care.

[27]  K. Flegal,et al.  Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. , 2000, Diabetes care.

[28]  G. Treviño.  Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation , 2007, Diabetes Care.

[29]  W. Knowler,et al.  Relationship of Glycosylated Hemoglobin to Oral Glucose Tolerance: Implications for Diabetes Screening , 1988, Diabetes.

[30]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[31]  Naoko Tajima,et al.  Is the measurement of glycated hemoglobin A1c alone an efficient screening test for undiagnosed diabetes? Japan National Diabetes Survey. , 2007, Diabetes research and clinical practice.

[32]  M. Engelgau,et al.  Screening for type 2 diabetes. , 2000, Diabetes care.

[33]  R. Little,et al.  Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. , 2005, Clinical chemistry.

[34]  R. Kalyani,et al.  Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. , 2006, JAMA.

[35]  B. Zinman,et al.  Impaired Fasting Glucose and Impaired Glucose Tolerance , 2007, Diabetes Care.

[36]  E. Barrett-Connor,et al.  Isolated Postchallenge Hyperglycemia and the Risk of Fatal Cardiovascular Disease in Older Women and Men: The Rancho Bernardo Study , 1998, Diabetes Care.

[37]  R. Klein,et al.  Glycated haemoglobin, plasma glucose and diabetic retinopathy: cross-sectional and prospective analyses , 1993, Diabetologia.

[38]  R. Holman,et al.  Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). , 1999, American heart journal.

[39]  G. Moneta,et al.  Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes , 2007 .

[40]  Ciprian M Crainiceanu,et al.  Short-term variability in measures of glycemia and implications for the classification of diabetes. , 2007, Archives of internal medicine.

[41]  R. Klein,et al.  Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.

[42]  Cas Weykamp,et al.  IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. , 2004, Clinical chemistry.

[43]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[44]  K. Shima,et al.  The Response of GHb to Stepwise Plasma Glucose Change Over Time in Diabetic Patients , 1993, Diabetes Care.

[45]  W. Herman.  Diabetes Epidemiology: Guiding Clinical and Public Health Practice , 2007, Diabetes Care.

[46]  Rhodri Hayward,et al.  Screening , 2008, The Lancet.

[47]  C. Sumner,et al.  The spectrum of neuropathy in diabetes and impaired glucose tolerance , 2003, Neurology.

[48]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[49]  D. Singer,et al.  Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. , 1996, Journal of clinical epidemiology.

[50]  D. Sacks.  Global harmonization of hemoglobin A1c. , 2005, Clinical chemistry.

[51]  B. Balkau,et al.  Use of HbA1c in Predicting Progression to Diabetes in French Men and Women , 2006, Diabetes Care.

[52]  M. Engelgau,et al.  Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis. , 2005, Diabetes care.

[53]  J. Leahy.  Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care , 2008 .

[54]  G L Myers,et al.  The national glycohemoglobin standardization program: a five-year progress report. , 2001, Clinical chemistry.

[55]  J. Shaw,et al.  Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) , 2007, Circulation.

[56]  M. Carroll,et al.  Estimate of biological variation of laboratory analytes based on the third national health and nutrition examination survey. , 2005, Clinical chemistry.

[57]  R. Paroni,et al.  Approved IFCC Reference Method for the Measurement of HbA1c in Human Blood , 2002, Clinical chemistry and laboratory medicine.

[58]  L. Bry,et al.  Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. , 2001, Clinical chemistry.

[59]  T. Dudley,et al.  Utility of hemoglobin A1c in predicting diabetes risk , 2004, Journal of General Internal Medicine.

[60]  P. H. Petersen,et al.  Consequences Of Bias and Imprecision in Measurements of Glucose and Hba1c for the Diagnosis and Prognosis of Diabetes Mellitus , 2005, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[61]  W. Knowler.  Screening for NIDDM: Opportunities for detection, treatment, and prevention , 1994, Diabetes Care.

[62]  D. Schriger,et al.  Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes , 2000, Journal of General Internal Medicine.

[63]  R. Hanås.  Psychological impact of changing the scale of reported HbA(1c) results affects metabolic control. , 2002, Diabetes care.

[64]  M. Matsumoto,et al.  The combination of fasting plasma glucose and glycosylated hemoglobin predicts type 2 diabetes in Japanese workers. , 2007, Diabetes research and clinical practice.

[65]  S. Manley.  Haemoglobin A1c – A Marker for Complications of Type 2 Diabetes: The Experience from the UK Prospective Diabetes Study (UKPDS) , 2003, Clinical chemistry and laboratory medicine.

[66]  R. Little.  Glycated Hemoglobin Standardization – National Glycohemoglobin Standardization Program (NGSP) Perspective , 2003, Clinical chemistry and laboratory medicine.

[67]  M. Engelgau,et al.  The Onset of NIDDM and its Relationship to Clinical Diagnosis in Egyptian Adults , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[68]  F. Ovalle,et al.  Artificially low hemoglobin A1c caused by use of dapsone. , 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[69]  David M Nathan,et al.  Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus , 2002, Annals of Internal Medicine.

[70]  D. Goldstein,et al.  Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. , 2002, Diabetes care.

[71]  M. Engelgau,et al.  A multivariate logistic regression equation to screen for dysglycaemia: development and validation , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[72]  M. Harris,et al.  Undiagnosed NIDDM: Clinical and Public Health Issues , 1993, Diabetes Care.